Weight-loss drugs seem to have stalled growth in bariatric surgeries for Intuitive Surgical. CEO Gary Guthart says on a call with analysts that the ongoing deceleration in the weight-loss surgeries had continued, and the surgeries were flat year-on-year in 1Q. The company has flagged GLP-1 drugs affecting bariatric procedure numbers in previous quarters, but 1Q was the first period when the procedures did not grow. The lower end of the company’s guidance range assumes continued weakness in bariatric surgeries, while the upper end assumes flat to slightly positive procedures. Shares are up 3.6%, to $386, after hours.